| Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of … AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, O Degen, ... The Lancet 393 (10189), 2428-2438, 2019 | 1026 | 2019 |
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients M Laguno, J Murillas, JL Blanco, E Martínez, R Miquel, ... Aids 18 (13), 27-36, 2004 | 510 | 2004 |
| Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection E Martínez, JA Arnaiz, D Podzamczer, D Dalmau, E Ribera, P Domingo, ... New England Journal of Medicine 349 (11), 1036-1046, 2003 | 388 | 2003 |
| Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy A Suy, E Martínez, O Coll, M Lonca, M Palacio, E de Lazzari, M Larrousse, ... Aids 20 (1), 59-66, 2006 | 243 | 2006 |
| A dendritic cell–based vaccine elicits T cell responses associated with control of HIV-1 replication F García, N Climent, AC Guardo, C Gil, A León, B Autran, JD Lifson, ... Science translational medicine 5 (166), 166ra2-166ra2, 2013 | 239 | 2013 |
| Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study) AK Sullivan, D Raben, J Reekie, M Rayment, A Mocroft, S Esser, A Leon, ... PloS one 8 (1), e52845, 2013 | 205 | 2013 |
| Incidence and causes of death in HIV‐infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from … E Martinez, A Milinkovic, E Buira, E De Lazzari, A Leon, M Larrousse, ... HIV medicine 8 (4), 251-258, 2007 | 149 | 2007 |
| A therapeutic dendritic cell-based vaccine for HIV-1 infection F García, N Climent, L Assoumou, C Gil, N González, J Alcamí, A León, ... Journal of Infectious Diseases 203 (4), 473-478, 2011 | 143 | 2011 |
| mHealth interventions to support self-management in HIV: a systematic review V Cooper, J Clatworthy, J Whetham, EmERGE Consortium The open AIDS journal 11, 119, 2017 | 137 | 2017 |
| Early virological failure with a combination of tenofovir, didanosine and efavirenz D Podzamczer, E Ferrer, JM Gatell, J Niubo, D Dalmau, A Leon, H Knobel, ... Antiviral Therapy 10 (1), 171-177, 2005 | 117 | 2005 |
| Early virological failure with a combination of tenofovir, didanosine and efavirenz D Podzamczer, E Ferrer, JM Gatell, J Niubo, D Dalmau, A Leon, H Knobel, ... Antiviral Therapy 10 (1), 171-177, 2005 | 117 | 2005 |
| A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected … E Martínez, JA Arranz, D Podzamczer, M Loncá, J Sanz, P Barragán, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (3), 290-297, 2009 | 114 | 2009 |
| A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study A León, C Cáceres, E Fernández, P Chausa, M Martin, C Codina, ... PloS one 6 (1), e14515, 2011 | 109 | 2011 |
| A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study A León, C Cáceres, E Fernández, P Chausa, M Martin, C Codina, ... PloS one 6 (1), e14515, 2011 | 109 | 2011 |
| Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine A León, E Martinez, J Mallolas, M Laguno, JL Blanco, T Pumarola, ... Aids 19 (2), 213-215, 2005 | 94 | 2005 |
| Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts* E De Lazzari, A Leon, JA Arnaiz, E Martinez, H Knobel, E Negredo, ... Hiv Medicine 9 (4), 221-226, 2008 | 92 | 2008 |
| Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir E Martínez, P Domingo, MJ Galindo, A Milinkovic, JA Arroyo, F Baldoví, ... Clinical Infectious Diseases 38 (7), 1017-1023, 2004 | 92 | 2004 |
| Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1 … F García, JCLB de Quirós, CE Gómez, B Perdiguero, JL Nájera, ... Vaccine 29 (46), 8309-8316, 2011 | 85 | 2011 |
| The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients A Milinkovic, E Martinez, S López, E De Lazzari, O Miró, S Vidal, ... Antiviral therapy 12 (3), 407-416, 2007 | 85 | 2007 |
| Therapeutic vaccines against HIV infection F García, A León, JM Gatell, M Plana, T Gallart Human vaccines & immunotherapeutics 8 (5), 569-581, 2012 | 84 | 2012 |
